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ABSTRACT 
Pneumonia is a fatal infection with hard time breathing, cough, and fever. The children are at high risk worldwide due to pneumonia. This is 
responsible for childhood mortality and morbidity worldwide. It is mainly caused by bacteria. Pneumonia-causing bacteria are resistant to most of 
the antibiotics and therapeutic agents due to the formation of biofilms. Laboratories around the world are trying to develop strategies to combat 
pneumococcal biofilms. This review deals with the formation of pneumococcal biofilms and their different intervention strategies.  
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Pneumonia is a lung infection with a cough, fever and hard time 
breathing. Traditionally pneumonia is cured at home and often clears 
up in 2 to 3 w. But old age people, babies, and medically challenged 
people need special care and medication. Pneumonia is mainly caused 
by bacteria like Streptococcus pneumoniae, Klebsiella pneumoniae, 
Hemophilus influenzae, Staphylococcus aureus, Mycoplasma 
pneumoniae, Legionella pneumoniae and Chlamydia pneumoniae. 
According to WHO pneumonia is the single largest cause of death in 
children worldwide. It kills an estimated 1.1 million children under the 
age of five years, accounting for 18% of all deaths of children every 
year worldwide. Pneumonia is most prevalent in South Asia and Sub-
Saharan Africa. In 2013, WHO and UNICEF launched an integrated 
Global Action Plan for Pneumonia and Diarrhea (GAPPD). The aim was 
to accelerate pneumonia control with a combination of interventions 
to protect, prevent, and treat pneumonia in children with actions to:  
• Protect children from pneumonia include promoting exclusive 
breastfeeding and adequate complementary feeding. 
• Prevent pneumonia with vaccinations, soap hand washes, 
reducing household air pollution, HIV prevention and cotrimoxazole 
prophylaxis for HIV-infected and exposed children. 
• Treat pneumonia which is focused on making sure that every 
sick child has access to the right kind of care (either from a 
community-based health worker or in a health facility if the disease 
is severe) and can get the antibiotics and artificial oxygen they need 
to get well [1] 
Due to biofilm formation and associated horizontal gene transfer, 
the microbes (pathogenic species) are becoming resistant to the 
commercially available antibiotics. Biofilms are the accumulation of 
microbial cells which grow on surfaces with a matrix of extracellular 
polymeric substances (EPS) on them. Naturally, biofilms consist of 
mixed microbial species. Bacterial cells secrete EPS using quorum 
sensing mechanism and lead to the formation of biofilm [2]. Biofilms 
help bacteria to protect them from antibiotics, host immune 
response and predation [3]. Naturally, biofilms can be formed by 
most of the microorganisms. Biofilm protects microorganisms from 
various environmental challenges such as metal toxicity, salinity, 
and pH [4]. It has been estimated that the frequency of infections 
caused by biofilms, especially in the developed world, lies between 
65% and 80% as per reports from Centres for Disease Control and 
Prevention (CDC) and National Institutes of Health (NIH) [5]. The 
pathogenic potential of carcinogenic bacteria in plaque biofilms is 
found to be modulated [6]. Most pathogenic organisms like 
Streptococcus, E. coli, Klebsiella, Pseudomonas, S. aureus, Enterococcus 
faecalis which grow on catheters, artificial joints, mechanical heart 
valves, etc lead to persistent infections [7]. EPS is composed of 
surfactants-lipids, extracellular DNA, extracellular proteins and 
exopolysaccharides. The composition of EPS determines the 
blooming and distribution of biofilms and antibiotic response. 
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Fig. 1: Showing different stages of biofilm formation (self-drawn in MS Powerpoint) 
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Virulence and pneumococcal biofilms 
Naturally, biofilms have a complex, dynamic and heterogeneous 
structure. Biofilm formation (fig. 1) imparts cells an adaptive strategy 
for survival in adverse conditions. The biofilm formation and 
maintenance depends on the production and amount of Extracellular 
Polymeric Substances (EPS). The environment surrounding the cells in 
a biofilm is known as the microenvironment. This microenvironment 
is determined by the physicochemical properties like concentration, 
adhesion, charge, sorption capacity, specificity and nature of the 
individual components of EPS as well as the three-dimensional 




















Fig. 2: Showing host-pneumococci interaction (self-drawn in MS powerpoint) 
 
Fig. 2 shows the factors that are responsible for host-pneumococci 
interaction. Biofilm formation in S. pneumoniae is influenced by the 
presence of both extracellular DNA and certain proteins. The 
encapsulated S. pneumoniae is found to be virulent because of the 
presence of capsular polysaccharide. Some researchers found out 
that under continuous culture conditions, biofilm formation is 
accompanied by an increase in the concentration of various kinds of 
proteins involved in virulence, adhesion, and resistance [9]. 
Furthermore, it has been shown that there is an overexpression of 
pneumolysin-coding gene under continuous culture conditions and 
repression under polystyrene grown biofilms. [10,11]. The role in 
biofilm formation of choline binding proteins, which anchor to the 
choline residues of the cell wall teichoic acids was studied in various 
mutants. It was found that Lyt lysozyme, Lyt Amidase, Lyt B 
Glucosaminidase, Cbpa adhesin, PcpA putative adhesin and PspA 
(pneumococcal surface protein A) mutants were poor biofilm 
formers compared to Pce phosphocholinesterase or CbpD putative 
amidase mutants [12]. Recently, about 69 mutants with insertions in 
42 different genes and 8 promoters have been identified with 
altered biofilm formation [13]. More recently using genetic 
dissection of developmental stages of biofilm revealed that biofilm 
formation involves multiple, convergent signaling pathways and a 
genetic program for the transition from planktonic growth state to the 
biofilm mode of growth. In Streptococcus pneumoniae, the induction of 
genetic competence favors the growth of biofilm. The induction and 
maintenance of genetic competence are regulated by a CSP-mediated 
quorum sensing system in transformable streptococci [14]. 
Pneumococcal biofilms and antimicrobial chemotherapy 
A current estimation reveals that 60 % of all bacterial infections are 
the result of biofilms of microorganisms and of the resistance of 
these communities to antibiotic agents and host immune defense 
mechanisms. However, the most significant evidence of the 
pathogenic relationship between humans and biofilms is based on 
the microscopic observations that have revealed the presence of 
these communities at the site of infection (otitis caused by 
pneumococci, endocarditis by Staphylococci, Pseudomonas in the 
lungs of patients with cystic fibrosis, etc) or in implants recovered 
from patients [15]. The most effective procedure for control of such 
infections is to prevent or stop the colonization of the organisms and 
its biofilm formation. Many antibiotics have been used for the 
purpose but most of these strategies proved ineffective because the 
use of antibiotics further provoke secondary nosocomial infections 
leading to morbidity and mortality worldwide and is a matter of 
further concern with increasing economic and human impact 
because of population density. Antimicrobial drugs are very 
frequently administered against nosocomial infections and through 
selection and exchange of genetic resistance elements; antibiotics 
promote the appearance of multidrug resistant, as well as extremely 
drug-resistant strains of bacteria. Microorganisms in the normal 
human flora sensitive to the given drug are suppressed, while 
resistant strains persist and may become endemic in the hospital 
environment. The widespread use of antimicrobials for therapy or 
prophylaxis (including topical) is the major determinant of 
resistance. Many strains of Pneumococci, Staphylococci, Enterococci, 
and Mycobacterium tuberculosis are currently resistant to most or all 
antimicrobials which were once effective. Multi resistant Klebsiella 
and Pseudomonas aeruginosa are prevalent in many hospitals [16]. 
Some researchers have found out that the phage lytic enzyme (Cpl-
1) prevent the formation of the biofilm of Streptococcus in the 
middle ear during otitis media [17]. A genetically engineered phage 
lysin had been remarkably used in the treatment of biofilm of E. coli 
which has been found that 99% of the biofilm has been eliminated 
[18]. It has been reported that an organic compound cis-2-decanoic 
acid induces the dispersion of biofilm of P. aeruginosa cells and some 
gram-positive species [19]. A study of the concomitant DNA and 
quorum sensing system via genetic transformation has been done in 
planktonic cultures [20]. It would enable the study of issues such as 
the passive resistance to antibiotics of the communities as well as 
the antibiotic tolerance. Alternatively, it is thought that the 
honeycomb structure of the EPS is a distinct feature of each 
organism indicating the role of genetic control in their formation 
[21]. The emergences of infectious diseases are still the causes of 
many deaths and tragedies [22]. Along with the emergence of new 
causal agents of infectious diseases (AIDS, Lyme, Ebola), old 
acquaintances, such as P. aeruginosa, Staphylococcus, Pneumococcus 
and many more, as well as apparently innocuous bacteria, such as 
Legionella started to reveal their extraordinary versatility and giving 
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rise to complex structures of biofilms. It is now known that today the 
most common mode of infection is the biofilm [9]. 
Intervention strategies 
One of the prime thirsts of modern-day medical microbiology is to 
look for agents that can destroy biofilms. Laboratories around the 
world are trying to develop anti-biofilm agents against biofilms of 
different organisms. Categorically these are as follows:  
1. Antimicrobial agents: Studies have previously reported that 
higher resistance to penicillin, tetracycline, rifampicin, amoxicillin, 
erythromycin, clindamycin, and levofloxacin is manifested by 
pneumococcal biofilms [23, 24]. Pneumococcal biofilms formed on 
the nasopharyngeal tissue of mouse were more resistant to 
gentamicin and penicillin G than did planktonic cell [25].  
2. Quorum sensing inhibitors: In S. pneumoniae, quorum sensing 
(QS) signaling regulates biofilm communities and plays a key role in 
coordinating the spatial disposition, aggregation of cells, and 
exopolysaccharide formation. Sinefungin, a nucleoside analogue of S-
adenosylmethionine, have shown a significant effect on 
pneumococcal biofilm formation in vitro and inhibit colonisation of 
pneumococcal biofilm in vivo by decreasing the AI-2 production and 
down-regulating gene expression [26]. In bacteria, the alteration of 
pathogenic gene expression and the methylation of adenine in the 
DNA duplex and of macromolecules are executed by DNA adenine 
methyltransferase (Dam) during the activated methyl cycle (AMC). 
AMC is involved in the biosynthesis of quorum sensing molecules 
that regulate competence and biofilm formation in pneumococci. 
The effect of a small molecule Dam inhibitor, pyrimidinedione, on 
Streptococcus pneumoniae biofilm formation and evaluated the 
changes in global gene expression within biofilms [27]. Their study 
reported that pyrimidinedione inhibits pneumococcal biofilm 
growth in vitro at concentrations that do not inhibit planktonic cell 
growth and downregulates important metabolic-, virulence-, 
competence-, and biofilm-related genes. Macrolides or quinolones 
alone or in combinations may be used to target not only intracellular 
pathogens but also their quorum sensing mechanisms and reduce 
the host inflammatory response [28].  
3. Novel organic and inorganic chemicals: Streptococcus 
pneumonia, a Gram-positive bacterium is a human respiratory tract 
pathogen which depends on a conserved β-carbonic anhydrase (CA, 
EC 4.2.1.1) for in vitro growth intracellularly and extracellularly. So, 
it is to be expected that the transmission and pathogenesis of the 
bacterium pneumococcal carbonic anhydrase (PCA) which it is a 
potential therapeutic target. Inorganic anions such as cyanate, 
bromide, selenocyanate, chloride, trithiocarbonate, iodide and 
cyanide were effective inhibitors of PCA. Sulfamide, sulfamic acid, 
phenylboronic, phenylarsonic acid, diethyldithiocarbamate and 
sulfonamide acetazolamide showed a significant effect on PCA [29]. 
A compound named cis-2-decanoic acid released from P. aeruginosa 
can disperse biofilms of E. coli, K. pneumoniae, P. mirabilis, S. 
pyogenes, B. subtilis, S. aureus and C. albicans [19]. 
4. Biosurfactants: Biosurfactants are amphiphilic compounds of 
biological origin containing a hydrophilic region (polar or non-polar) 
and a hydrophobic region (lipid or fatty acid). Biosurfactants have 
been identified in many biological processes as the components of 
cellular metabolism, motion, and defense. They are found 
abundantly in bacteria, in biofilms as quorum-sensing molecules, 
lubricants, promoting the uptake of poorly soluble substrates, as 
virulence factors, antimicrobial compounds, immune modulators 
and secondary metabolites [30]. Lipopeptide, a class of 
biosurfactants which is released from Bacillus tequilensis was found 
to inhibit biofilm formation of E. coli and S. mutans [31]. Mixed 
biosurfactants like lunasan extracted from Lactococcus lactis and 
Streptococcus thermophilus was reported to be effective against 
Staphylococcus, Streptococcus, Rothia and Candida sp. [32]. A 
nonspecific class of biosurfactants like rufisan extracted from 
Candida lypolytica was effective against Streptococcal biofilms [33].  
5. Nanoparticles: Silver coated polyvinyl pyrrolidone 
nanoparticles was reported to be effective against capsular 
polysaccharide influenced bacteriocidal effect against Streptococcus 
pneumoniae [34]. The Aspergillus flavus mediated silver 
nanoparticles is found to be effective against many human 
pathogens like E. coli, B. subtilis, S. flexneri, E. faecalis, K. pnemoniae, 
S. epidermis and P. mirabilis [35]. 
6. Natural products including phytochemicals: Two prenylated 
flavonoid derivatives, sanggenon G and sanggenol A was reported to 
inhibit pneumococcal NAs and, in contrast to the approved NA 
inhibitor oseltamivir, as well as also the planktonic growth and 
biofilm formation of Pneumococci [36]. Bioactive compounds of 
aqueous fraction of the dried fruit of Lagenaria siceraria was 
evaluated in vitro and found to be highly active against Streptococcus 
pneumoniae biofilm with (MIC 2.5 mg/ml and MBC 5 mg/ml). The 
phytochemical investigation shows the presence of flavonoids, 
hydrolysable tannin, sterol, quinine, and phenols [37]. A study 
showed that Shin’iseihaito a Japanese herbal remade consists of 
rhizome of Anemarrhena asphodeloides, rhizome of Cimicifuga 
heracleifolia, leaf of Eriobotrya japonica, Gypsum fibrosum, fruit 
of Gardenia jasminoides, bulb of Lilium lancifolium, flower 
of Magnolia salicifolia, tuber of Ophiopogon japonicus, and the root 
of Scutellaria baicalensis significantly inhibited the formation of 
biofilm from S. pneumoniae ATCC 49619 as well as significantly 
suppressed the biofilm formation by different S. pneumoniae clinical 
isolates also [38]. The ethyl acetate and methanol extract of Gymnema 
sylvestre have an antibiofilm effect on Streptococcus pyogenes from 
upper respiratory tract patients [41]. The methanol extract of 
Plectonthus amboinicus is reported to have an antibiofilm effect on 
Streptococcus pyogenes isolated from pharyngitis patients [42]. 
In another study of the plant extract of Rubus ulmifolius Schott., rich 
in ellagic acid, and ellagic acid derivatives, inhibited the formation of 
pneumococcal biofilms in a dose-dependent manner. As measured 
by viability assay, 100 and 200 mg/ml of 220D-F2 had significant 
bactericidal activity against pneumococcal planktonic cultures as 
early as 3 h post-inoculation having MIC’s 80 mg/ml of 220D-F2 
which completely eradicated overnight cultures of planktonic 
Pneumococci [39]. 
7. Extracellular polymerase substance degrading enzymes:  
Dornase alpha is a highly purified form of recombinant human DNase I 
(rhDNase I) that has been shown to be effective against the established 
biofilms of Streptococcus pneumoniae. It was reported that DNase 
treatment resulted in significant degradation of a biofilm (by 66.7% to 
95%), even though the biofilms were grown for 6 d [40, 4]. 
CONCLUSION 
Pneumonia-causing Bacterial biofilms are responsible for childhood 
mortality worldwide. The recent trend on biofilm research not only aims 
at the intervention strategies and combating pneumococcal biofilm 
formation by antimicrobial chemotherapy which indirectly promotes the 
growth of bacteria but also many strategies are used to stop colonization 
of the bacteria and its biofilm formation. Such strategies are quorum 
sensing inhibitors like sinefungin and pyrimidinedione, inorganic and 
organic chemicals like cyanate, bromide, selenocyanate, chloride, 
trithiocarbonate, iodide and cyanide, sulfamide, sulfamic acid, 
phenylboronic, phenylarsonic acid, diethyldithiocarbamate and 
sulfonamide acetazolamide and cis-2-decanoic acid, biosurfactants like 
lipopeptide, lunasan and rufisan, many natural products like 
phytochemicals and extracellular polymerase degrading enzymes like 
Dornase alpha and nanoparticles are reported to have activity against 
pneumococcal biofilms. Advance research for establishing some of the 
assured strategies for the effective intervention of pathogenic biofilm 
requires further in-depth research in the subject. 
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